Welcome to our dedicated page for Bwx Technologies news (Ticker: BWXT), a resource for investors and traders seeking the latest updates and insights on Bwx Technologies stock.
BWX Technologies, Inc. (NYSE: BWXT) generates news across defense, clean energy, nuclear medicine, space exploration and environmental restoration because of its focus on nuclear technologies and engineering services. Company announcements highlight work in both Government Operations and Commercial Operations, including naval nuclear component production, special materials processing, commercial nuclear components, field services, fuel and fuel handling, and medical-related activities.
News for BWXT often covers contracts and projects tied to the U.S. Naval Nuclear Propulsion Program and the U.S. government. For example, the company has reported a U.S. Naval Nuclear Propulsion Program contract for the manufacture of naval nuclear reactor fuel through its subsidiary Nuclear Fuel Services, Inc., which supplies fuel used in U.S. Navy submarines and aircraft carriers. Updates can also involve advanced fuel technologies such as TRISO nuclear fuel and programs like Project Pele, a microreactor prototype that uses Generation IV high-temperature gas-cooled reactor technology.
Commercial and international project news includes roles such as Owner’s Engineer for new nuclear build projects and collaboration with advanced reactor developers. BWXT has announced Owner’s Engineer services for Bulgaria’s New Build Kozloduy Nuclear Power Plant Units 7 and 8 as part of a consortium, and agreements with Rolls-Royce SMR involving nuclear steam generator design and potential future component supply for small modular reactors. These items illustrate how BWXT participates in large nuclear energy projects and advanced reactor supply chains.
Investors and observers can also expect BWXT news about quarterly financial results, non-GAAP performance metrics, capital markets transactions such as convertible senior notes offerings, and changes in senior leadership roles reported through press releases and Form 8-K filings. For ongoing insight into BWXT’s contracts, advanced nuclear initiatives and financial updates, this news page aggregates company disclosures and related coverage in one place.
BWX Technologies (NYSE: BWXT) announced it has secured the second phase of a contract from the Wyoming Energy Authority. This contract aims to assess the deployment of small-scale nuclear reactors in Wyoming as part of a resilient energy strategy. Phase one focused on defining nuclear application requirements and identifying Wyoming's supply chain capabilities. The $20 million cost-share program's phase two will involve conceptual design, regulatory planning, and demonstrating manufacturing capabilities. Completion is expected by Q3 2025. The initiative leverages the U.S. Department of Energy's Advanced Reactor Demonstration Program achievements and involves collaboration with Idaho National Laboratory.
BWX Technologies (BWXT) announced a $30 billion contract from the U.S. Department of Energy's National Nuclear Security Administration (DOE/NNSA) for managing and operating the Pantex Plant. The initial contract term is five years, with the possibility of three additional five-year options, extending to 20 years if fully exercised. The contract was awarded to PanTeXas Deterrence (PXD), a joint venture led by a BWXT subsidiary, including Fluor, SOC, A Day & Zimmermann Company, and The Texas A&M University System. Pantex is important for maintaining the U.S. nuclear weapons stockpile, supporting life extension programs, and other nuclear operations. The transition period will last four months, starting on an undetermined date.
BWXT Medical has submitted a Drug Master File (DMF) to the FDA for its No Carrier Added (n.c.a.) Actinium-225 (Ac-225) Active Pharmaceutical Ingredient. Ac-225 is an alpha-emitting isotope important for targeted alpha therapies (TATs) that selectively kill cancer cells. The DMF submission highlights BWXT's commitment to quality and regulatory standards, ensuring safety and efficacy. The isotope is produced via high-energy proton spallation of thorium targets, a method developed in collaboration with TRIUMF to yield high purity Ac-225. This filing supports clinical and pharmaceutical developments, marking a significant milestone for BWXT Medical.
BWX Technologies, Inc. reported strong first quarter 2024 results with revenues of $604.0 million, net income of $68.5 million, and adjusted EBITDA of $115.2 million. The company reaffirmed its 2024 non-GAAP EPS guidance of $3.05-$3.20. BWXT highlighted expansion plans for its Cambridge manufacturing plant to serve global markets and emphasized opportunities in nuclear technologies. The company remains focused on operational excellence and innovation to achieve its financial targets.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.